ZBTB11 Promotes Breast Cancer Progression by Activating FBXO28‐Mediated MST1 Degradation and Suppressing Hippo Signaling
Source abstract
Abstract
ABSTRACT Epithelial‐mesenchymal transition (EMT) is a key driver of breast cancer progression, yet the upstream transcriptional and ubiquitin‐mediated mechanisms that modulate Hippo signaling remain incompletely defined. In this study, we identify a regulatory axis in which the transcription factor ZBTB11 promotes breast cancer aggressiveness by enhancing the expression of the F‐box protein FBXO28. ZBTB11 directly binds to the FBXO28 promoter and increases its transcription, leading to elevated FBXO28 protein levels. We show that FBXO28 functions as an E3 ubiquitin ligase that targets the core Hippo kinase MST1 for K48‐linked ubiquitination and proteasomal degradation. Reduction of MST1 diminishes Hippo pathway activity, resulting in decreased phosphorylation and enhanced nuclear accumulation of Yes‐associated protein (YAP) and transcriptional coactivator with PDZ‐binding motif (TAZ), which subsequently activates EMT‐related gene expression. Functionally, disruption of the ZBTB11‐FBXO28‐MST1 axis suppresses EMT, migration, invasion, and tumor growth in vitro and in vivo, whereas reintroduction of FBXO28 or depletion of MST1 reverses these effects. Together, our findings reveal a previously unrecognized transcription‐ubiquitination cascade that modulates Hippo signaling and contributes to breast cancer progression, highlighting this axis as a candidate therapeutic vulnerability that warrants further validation for limiting metastasis.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Hippo pathway signaling and YAP/TAZ · Cancer Cells and Metastasis · Wnt/β-catenin signaling in development and cancer
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of General Surgery Northern Jiangsu People's Hospital Affiliated to Yangzhou University Yangzhou Jiangsu China
Department of Thyroid and Breast Surgery Xinghua People's Hospital Affiliated to Yangzhou University Xinghua Jiangsu China
Department of Thyroid and Breast Surgery Changxing Hospital of Traditional Chinese Medicine Huzhou Zhejiang China
Funding
National Natural Science Foundation of China
References (47)
Show source-provided references
1. 10.1016/j.breast.2022.08.01010.1016/j.breast.2022.08.010 ↗
2. 10.1186/s12905‐025‐03961‐310.1186/s12905‐025‐03961‐3 ↗
3. 10.17305/bb.2024.1110310.17305/bb.2024.11103 ↗
4. 10.1038/s41698‐018‐0047‐010.1038/s41698‐018‐0047‐0 ↗
5. 10.3390/cancers1421532710.3390/cancers14215327 ↗
6. 10.3390/biomedicines1102061810.3390/biomedicines11020618 ↗
7. 10.1038/nrc262010.1038/nrc2620 ↗
8. High‐Throughput Cellular Heterogeneity Analysis in Cell Migration at the Single‐Cell Level10.1002/smll.202206754 ↗
9. Application of PVA Hydrogel Loaded With Luteolin Nanoparticles in Anti EMT Treatment After GBM10.1016/j.mtbio.2025.101956 ↗
10. 10.3892/ijmm.2025.554310.3892/ijmm.2025.5543 ↗
11. 10.1186/1423‐0127‐19‐6710.1186/1423‐0127‐19‐67 ↗
12. Betulinic Acid Suppresses Breast Cancer Aerobic Glycolysis via Caveolin‐1/NF‐kappaB/c‐Myc Pathway10.1016/j.bcp.2019.01.016 ↗
13. 10.1002/mco2.7033310.1002/mco2.70333 ↗
14. DLAT Promotes Triple‐Negative Breast Cancer Progression via YAP1 Activation10.1080/15384047.2024.2421578 ↗
15. The Hippo Signalling Pathway and Its Implications in Human Health and Diseases10.1038/s41392-022-01191-9 ↗
16. The Hippo Pathway, YAP/TAZ, and the Plasma Membrane10.1016/j.tcb.2019.10.005 ↗
17. The Hippo Pathway: Biology and Pathophysiology10.1146/annurev-biochem-013118-111829 ↗
18. 10.1007/s12272‐021‐01322‐w10.1007/s12272‐021‐01322‐w ↗
19. The Biology of YAP/TAZ: Hippo Signaling and Beyond10.1152/physrev.00005.2014 ↗
20. YAP/TAZ as Master Regulators in Cancer: Modulation, Function and Therapeutic Approaches
21. 10.1186/s13046‐023‐02704‐210.1186/s13046‐023‐02704‐2 ↗
22. 10.1016/j.gendis.2023.01.01710.1016/j.gendis.2023.01.017 ↗
23. 10.1038/s41467‐025‐59309‐w10.1038/s41467‐025‐59309‐w ↗
24. 10.1016/j.cellsig.2025.11173810.1016/j.cellsig.2025.111738 ↗
25. 10.1016/j.jbc.2024.10720810.1016/j.jbc.2024.107208 ↗
26. 10.3892/etm.2021.1104110.3892/etm.2021.11041 ↗
27. FBXO28 Promotes Proliferation, Invasion, and Metastasis of Pancreatic Cancer Cells Through Regulation of SMARCC2 Ubiquitination[J]
28. 10.1186/s12885‐024‐11893‐810.1186/s12885‐024‐11893‐8 ↗
29. 10.1038/s41389‐022‐00433‐310.1038/s41389‐022‐00433‐3 ↗
30. 10.1002/emmm.20120234110.1002/emmm.201202341 ↗
31. 10.1038/s41467‐020‐19205‐x10.1038/s41467‐020‐19205‐x ↗
32. 10.1016/j.celrep.2022.11052410.1016/j.celrep.2022.110524 ↗
33. 10.1182/bloodadvances.202200958010.1182/bloodadvances.2022009580 ↗
34. 10.1007/s12672‐024‐01697‐410.1007/s12672‐024‐01697‐4 ↗
35. 10.1111/cpr.1332510.1111/cpr.13325 ↗
36. ZBTB11 Depletion Targets Metabolic Vulnerabilities in KRAS Inhibitor‐Resistant PDAC10.1038/s41589-025-01978-1 ↗
37. 10.1038/s41467‐024‐45585‐510.1038/s41467‐024‐45585‐5 ↗
38. 10.1126/science.126041910.1126/science.1260419 ↗
39. 10.1093/neuonc/noab24410.1093/neuonc/noab244 ↗
40. Verteporfin, a Suppressor of YAP‐TEAD Complex, Presents Promising Antitumor Properties on Ovarian Cancer10.2147/OTT.S109979 ↗
41. In Vitro Evaluation of Verteporfin and Exploration of TEAD Palmitoylation Inhibition in Piezo1‐YAP/TAZ Signaling and ECM Remodeling10.1038/s41598-025-28960-0 ↗
42. 10.1002/jcp.2861010.1002/jcp.28610 ↗
43. Distinct Thresholds Govern Myc's Biological Output in Vivo10.1016/j.ccr.2008.10.018 ↗
44. 10.3390/biom1407074910.3390/biom14070749 ↗
45. 10.1093/nar/gky112810.1093/nar/gky1128 ↗
46. ChIP‐Atlas 2021 Update: A Data‐mining Suite for Exploring Epigenomic Landscapes by Fully Integrating ChIP‐Seq, ATAC‐Seq and Bisulfite‐Seq Data10.1093/nar/gkac199 ↗
47. JASPAR 2024: 20th Anniversary of the Open‐Access Database of Transcription Factor Binding Profiles10.1093/nar/gkad1059 ↗